| Dr. Mark J. Poznansky | |
|---|---|
Poznansky in the 2008 Ontario Genomics Institute Annual Report |
|
| Born | April 25, 1946 Montreal, Canada |
| Residence | Toronto, Canada |
| Alma mater | McGill University |
| Occupation | Scientist and Consultant |
| Website | |
| G2G Consulting Website | |
Dr. Mark J. Poznansky, Ph.D., O.Ont, C.M. (born April 5, 1946) is a research scientist and science administrator. He is the President and CEO of the Ontario Genomics Institute (OGI) and was previously Chair of the Board of OGI, and the founder of G2G Consulting Inc. He is a member of the Order of Canada, a member of the Order of Ontario and the former CEO, President and former Scientific Director of Robarts Research Institute.
Contents |
Born in Montreal, Poznansky was educated at McGill University, receiving his PhD in Physiology in 1970. Poznansky completed his postdoctoral training in Biophysics at Harvard Medical School in 1972,[1] where he held the position of Lecturer in Biophysics until 1976. He also served as Charge de Recherche at the Collège de France in Paris from 1973 to 1974.
Poznansky returned to Canada in 1976, taking a position as Associate Professor of Physiology at the University of Alberta in Edmonton.[2] Over the next 18 years, he rose to the rank of Professor and his laboratory developed an international reputation both the areas of cholesterol [3] and membrane biophysics [4] as well as enzyme replacement therapy [5] and the development of novel approaches to drug delivery.[6] In 1984, Poznansky moved on to become the Associate Dean of Medicine at the University of Alberta in Edmonton, a position he held for 9 years.
In 1993, Poznansky arrived in London, Ontario, as President and Scientific Director of Robarts Research Institute. He presided over a period of growth, not only in funding and employment but in technology transfer as well. Under his helm from 1993 until 2007, Robarts Research Institute increased its staff from just over 100 to over 600.[7] Annual research funding increased from $10 million per year to over $40 million annually and the Institute spun out 7 different companies including one that was sold to GE Healthcare.
While at Robarts, Poznansky served as President and CEO of London-based Viron Therapeutics Inc. Under his helm, the company was able to bring a candidate drug to the start of Phase II and raised $20 million to support future research efforts.[8]
He also founded London Biotechnology Incubator Inc.,[9] Ontario’s first Life Sciences incubator. He was able to gain financial support to build a 50,000 sq. ft. facility in London.[10]
In 2008, Poznansky founded G2G Consulting Inc., offering a wide range of services - such as program reviews, mediation, strategic planning, change management, leadership training and mentoring and management restructuring - to government, hospitals, universities and institutions and the private sector..
Poznansky developed a process to help the Spanish government support the Life Sciences industry. He worked with the Canada Foundation for Innovation [11] to promote harmony among its committee members and to ensure they worked together to apportion available grant monies objectively.
He helped form a research partnership made up of Robarts Research Institute, Merck & Co, Merck Frosst Canada and GE Healthcare [12] that was able to receive funding of $20 million over four years, resulting in many key research findings and publications on the subject of lung disease. Poznansky helped change the way the University of Alberta, Edmonton conducted research and helped facilitate the amalgamation of the research administration that occurred when Ottawa Civic and Ottawa General Hospitals merged to create The Ottawa Hospital. He also aided the Thunder Bay Regional Institute in attracting not only some of the "most respected health research minds in Canada" [13] but those from around the globe.[14]
Poznansky has completed the Negotiation and Advanced Negotiation Workshops at the Harvard Negotiation Institute, Harvard Law School.
Poznansky was appointed as President and CEO of the Ontario Genomics Institute (OGI) on December 1, 2010.[15] His role at OGI draws on his substantive experience in the life sciences and in running institutes and businesses, as well as his knowledge of government affairs and business development.[16]
Poznansky is Chair of Let’s Talk Science,[17] Chief Science Advisor to the CEO of the Thunder Bay Regional Research Institute [18] and a board member of the Innovation Institute of Ontario.
Poznansky is a founding member and past Chair of the Council for Health Research in Canada,[19] a research advocacy group in Ottawa. He also chaired the Scientific Advisory Board of the Canadian Medical Discoveries Fund [9] and the board of MDS Capital Corp.[20]
He has sat on the boards of organizations such as Diabetogen, BioMark Inc. and TechAlliance, London. Poznansky has also been a member of numerous science-related committees including the Science Advisory Committee of the Heart and Stroke Foundation of Canada and the Medical Research Council of Canada Grants Panel.[21]
Poznansky lectures widely – both nationally and internationally – on subjects related to the biopharmaceutical industry and research and administration and funding, including technology transfer. He also lectures on Jewish medical ethics as it pertains to human and animal experimentation.[22]
In 2005, Poznansky was made a member of the Order of Canada [23] and a member of the Order of Ontario.[24] He is also the recipient of the Queen Elizabeth II Golden Jubilee Medal.[9]
Poznansky led the development of the book Using Our Heads, "a celebration of innovation that was supported by the Ontario Innovation Trust (OIT)." [25]